Abstract:An integrative review aimed to identify key miRNAs for distinguishing AD patients from cognitively healthy individuals. Notable miRNAs included miRNA‐30a‐3p, miRNA‐193a‐5p, miRNA‐143‐3p, miRNA‐145‐5p. Pathway enrichment analysis highlighted the significance of the MAPK pathway, which plays a vital role in AD‐related events. These findings offer potential for AD diagnostic tests and monitoring disease progression. Furthermore, further exploration of these signalling pathways contributes to a deeper understanding of AD pathophysiology. Alzheimer's disease (AD) is the most common type and accounts for 60%–70% of the reported cases of dementia. MicroRNAs (miRNAs) are small non‐coding RNAs that play a crucial role in gene expression regulation. Although the diagnosis of AD is primarily clinical, several miRNAs have been associated with AD and considered as potential markers for diagnosis and progression of AD. We sought to match AD‐related miRNAs in cerebrospinal fluid (CSF) found in the GeoDataSets, evaluated by machine learning, with miRNAs listed in a systematic review, and a pathway analysis. Using machine learning approaches, we identified most differentially expressed miRNAs in Gene Expression Omnibus (GEO), which were validated by the systematic review, using the acronym PECO—Population (P): Patients with AD, Exposure (E): expression of miRNAs, Comparison (C): Healthy individuals, and Objective (O): miRNAs differentially expressed in CSF. Additionally, pathway enrichment analysis was performed to identify the main pathways involving at least four miRNAs selected. Four miRNAs were identified for differentiating between patients with and without AD in machine learning combined to systematic review, and followed the pathways analysis: miRNA‐30a‐3p, miRNA‐193a‐5p, miRNA‐143‐3p, miRNA‐145‐5p. The pathways epidermal growth factor, MAPK, TGF‐beta and ATM‐dependent DNA damage response, were regulated by these miRNAs, but only the MAPK pathway presented higher relevance after a randomic pathway analysis. These findings have the potential to assist in the development of diagnostic tests for AD using miRNAs as biomarkers, as well as provide understanding of the relationship between different pathophysiological mechanisms of AD.

Determination of miR-373 and miR-204 levels in neuronal exosomes in Alzheimer's disease

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.

Alteration of miRNAs in Small Neuron-Derived Extracellular Vesicles of Alzheimer's Disease Patients and the Effect of Extracellular Vesicles on Microglial Immune Responses

Amyloid-beta protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease

Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease

Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease

Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

Human microRNA-153-3p targets specific neuronal genes and is associated with the risk of Alzheimer's disease.

Serum Sirtuin-1, HMGB1-TLR4, NF-KB and IL-6 Levels in Alzheimer's: The Relation Between Neuroinflammatory Pathway and Severity of Dementia

MicroRNA-135a and -200B, Potential Biomarkers for Alzheimer׳s Disease, Regulate Β Secretase and Amyloid Precursor Protein.

Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review

Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism

Genome-Wide Serum Microrna Expression Profiling Identifies Serum Biomarkers for Alzheimer'S Disease

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

MicroRNA-511-3p regulates Aβ1–40 induced decreased cell viability and serves as a candidate biomarker in Alzheimer's disease

Peripheral Blood Biomarkers CXCL12 and TNFRSF13C Associate with Cerebrospinal Fluid Biomarkers and Infiltrating Immune Cells in Alzheimer Disease

Correlation between abnormal cellular immune and changes of magnetic resonance spectroscopy in patients with Alzheimer's disease

MicroRNA-455-3P as a peripheral biomarker and therapeutic target for mild cognitive impairment and Alzheimer's disease

miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach